ABVC BioPharma Completes Partial Separation of BioKey Cayman

What Happened ABVC BioPharma, Inc. announced it completed previously disclosed Reorganization Transactions to partially separate its subsidiary BioKey (Cayman), Inc. (BioKey Cayman). BioKey Cayman filed a Form 10 (effective June 25, 2026) and became a separate Exchange Act reporting company. As of the Distribution Date (effective 11:59 p.m. EDT on August 21, 2026), ABVC distributed approximately 15% of BioKey Cayman’s issued and outstanding ordinary shares to ABVC common stockholders as a pro rata dividend, and ABVC remains the controlling holder with ~85% ownership.

Key Details

• Distribution ratio: 0.169464 BioKey Cayman ordinary share per ABVC common share (Record Date: July 24, 2026).
• Total distributed: 4,500,390 BioKey Cayman ordinary shares; distributed percentage ≈ 15% to ABVC shareholders.
• Corporate filings/agreements: BioKey Cayman’s Form 10 (effective June 25, 2026); Separation and Distribution Agreement (June 22, 2026) and related Transitional Services, Tax Matters, and Employee Matters Agreements (filed as Exhibits 2.1, 10.1, 10.2, 10.3).
• Market/quotation status: No trading market yet for BioKey Cayman ordinary shares; BioKey Cayman intends to apply for quotation on the OTC Markets.

Why It Matters This filing documents a formal corporate separation and a share distribution that gives ABVC shareholders direct ownership of a portion of BioKey Cayman while leaving ABVC as the majority owner. Investors should note BioKey Cayman is now a separate SEC reporting entity (Form 10) but its shares are not yet tradable — future liquidity depends on BioKey Cayman’s OTC listing process. The separation is governed by several agreements that allocate assets, liabilities, tax matters, employee matters and include mutual indemnities; these define ongoing relationships and potential responsibilities between ABVC and BioKey Cayman.